Featured News

We are pleased to share the video recording of Dr. Jocelyn Silvester discussing what you need to know about pediatric celiac disease now and in the future.

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

The following study, which examines the prevalence of dermatitis herpetiformis (DH), was made possible by the Foundation’s iCureCeliac® patient registry.

The Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).

Today, the U.S. Food and Drug Administration issued a final rule for gluten-free labeling compliance requirements for fermented and hydrolyzed foods.

Thanks to your generous support, we are deploying iCureCeliac and iQualifyCeliac, as well as other assets unique to the Foundation, to further celiac disease drug development.